Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross margin of tablets and capsules, while the remaining dosage forms have decreased to varying degrees; 3) increased R&D investment and cost rate optimization. (Mainichi Keizai Shimbun)
万联证券4月19日发布研报称，给予康缘药业（600557.SH）买入评级。评级理由主要包括：1）口服液和凝胶剂高增长；2）片丸剂和胶囊剂毛利率同比增长，其余剂型均有不同程度减少；3）研发投入增长，费用率优化。（每日经济新闻）
Wanlian Securities released a research report on April 19 stating that Kangyuan Pharmaceutical (600557.SH) was given a purchase rating. The main reasons for the rating include: 1) high growth in oral liquids and gels; 2) year-on-year increase in gross mar
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.